Title:

Flash Survey on SARS-CoV-2 Infections in Pediatric Patients on anti-Cancer Treatment

Ondrej Hrusak [1,2], Tomas Kalina [1,2], Joshua Wolf [3], Adriana Balduzzi [4], Massimo Provenzi [5], Carmelo Rizzari [6], Susana Rives [7], María del Pozo Carlavilla [8], Maria Eli Valerio Alonso [8], Nerea Domínguez Pinilla [9], Jean-Pierre Bourquin [10], Kjeld Schmiegelow [11], Andishe Attarbaschi [12], Pernilla Grillner [13], Karin Mellgren [14], J Ten Bosch van der Werff [15], Rob Pieters [16], Triantafyllia Brozou [17], Arndt Borkhardt [17], Gabriele Escherich [18], Melchior Lauten [19], Martin Stanulla [20], Owen Smith [21], Allen Eng Juh Yeoh [22], Sarah Elitzur [23], Ajay Vora [24], Chi-Kong Li [25], Hany Ariffin [26], Alexandra Kolenova [27], Luciano Dallapozza [28], Roula Farah [29], Jelena Lazic [30], Atsushi Manabe [31], Jan Styczynski [32], Gabor Kovacs [33], Gabor Ottoffy [34], Marisa Felice [35], Barbara Buldini [36], Valentino Conter [4], Jan Stary [2], Martin Schrappe [37]

[1] CLIP - Childhood Leukemia Investigation Prague, [2] Department of Pediatric Hematology, Charles University and Univ. Hospital Motol, Prague, Czechia, [3] Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA, [4] Clinica Pediatrica Universita degli Studi di Milano Bicocca, Monza, Italy, [5] Oncologia Pediatrica, Ospedale Papa Giovanni XXIII, Bergamo, Italy, [6] Pediatric Hematology Oncology Unit, Department of Pediatrics, University of Milano-Bicocca, MBBM Foundation, ASST Monza, [7] Hospital Sant Joan de Déu de Barcelona, Spain, [8] Hospital General Universitario de Albacete, Spain, [9] Hospital Virgen de la Salud, Spain, [10] Department of Oncology and Children's Research Center, University Children's Hospital Zurich, Zurich, Switzerland, [11] Department of Peadiatrics and Adolescent Medicine, Rigshospitalet University Hospital, Copenhagen, Denmark, [12] Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria, [13] Pediatric Oncology, Karolinska University Hospital, Sweden, [14] Department of Pediatric Haematology and Oncology, Sahlgrenska University Hospital, Gothenberg, Sweden, [15] UZ Brussels, Belgium, [16] Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands, [17] Department of Pediatric Oncology Hematology and Clinical Immunology Heinrich Heine University Dusseldorf, [18] Klinik für Pädiatrische Hämatologie und Onkologie Universtitätsklinikum Eppendorf, Hamburg, Germany, [19] University Hospital Schleswig-Holstein, Campus Lübeck, Germany, [20] Department of Pediatric Haematology and Oncology, Hannover Medical School, Hannover, Germany, [21] National Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Ireland, [22] Yong Loo Lin School of Medicine and Cancer Science Institute, National University of Singapore, and Viva-University Children's Cancer Centre, National University Hospital, Singapore, [23] Schneider Children's Medical Center of Israel, [24] Great Ormond Street Hospital, London, UK, [25] Department of Paediatrics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong, [26] University of Malaya Medical Centre, Kuala Lumpur, Malaysia, [27] Department of Pediatric Hematology and Oncology, Comenius University, Bratislava, Slovakia, [28] The Cancer Centre for Children, The Children's Hospital at Westmead, Australia, [29] LAUMC-Rizk Hospital, Beirut, Lebanon, [30] University Children`s Hospital, Belgrade, Serbia, [31] Hokkaido University in Sapporo, Japan, [32] Department of Pediatric Hematology and Oncology, Nicolaus Copernicus University, Bydgoszcz, Poland, [33] 2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary, [34] Oncohematology Unit, Dep. of Ped., University of Pécs, Hungary, [35] Hospital de Pediatría, "Prof. Dr. Juan P. Garrahan", Argentina, [36] Onco Hematology Unit, Dept. Salute della Donna e del Bambino, Università degli Studi di Padova, Italy, [37] Childrens Hospital Medical Center Schleswig-Holstein, Kiel, Germany

Abstract

Since the beginning of COVID-19 pandemics, it is known that the severe course of the disease occurs mostly among elderly, whereas it is rare among children and young adults. Comorbidities, in particular diabetes and hypertension, clearly associated with age, besides obesity and smoke are strongly associated with the need of intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Along the same line, anecdotal information from Wuhan, China mentioned a severe course of COVID-19 in a child treated for leukemia. Thus, we made a flash survey on COVID19 incidence among children on anticancer treatment. We received reports from 25 countries, where approximately 10,000 patients at risk are followed. At the time of the survey, over 200 of these children were tested, nine of whom were positive for COVID-19. Eight of the nine cases had asymptomatic to mild disease and one was just diagnosed with COVID-19. Thus, even children after anti-cancer chemotherapy may have a mild course. We also discuss preventive measures that are in place or should be taken as well as treatment options in immunocompromised children with COVID-19.

Introduction

The outbreak of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causing the Coronavirus Disease (COVID-19) pandemic in 2020 was identified in December, 2019. By March 17, 2020 it has affected 200,000 cases in 163 countries and in several foci the numbers rise exponentially [World Health Organization, "Rolling updates on coronavirus disease (COVID-19)" https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen]. In spite of high mortality rate, the spectrum of COVID-19 includes asymptomatic infection, upper respiratory tract infection, lower respiratory tract infection through severe respiratory failure, as well as other problems such as myocarditis, sepsis[1], and diarrhea (Pan et al, Am. J. Gastroenterol., In Press). The age distribution of the more severe course of the disease is strikingly skewed towards older patients, especially those over 65 years of age [1,2]. In contrast, pediatric patients rarely develop critical illness.[3–7] In one study, only 5% and 0.6% of 2141 evaluable children with confirmed COVID-19 had severe or critical illness respectively.[7] The biology underlying this disparity in severity is unknown.

The possibility that more severe disease associated with immunosenescence, along with an increased risk of severe disease in adults with cancer, and a single case report of a critically ill child who developed COVID-19 during myelosuppressive chemotherapy, has raised the concern that COVID-19 among immunosuppressed children might be a much more severe illness than is seen in otherwise healthy children. [2,8–10] This is consistent

with data for other coronaviruses, which do cause more severe infections in immunocompromised children.[11] To evaluate this, we used a flash survey to determine whether there was current evidence that pediatric patients with cancer in SARS-CoV-2 affected areas had been tested for this virus or had developed severe COVID-19 disease.

Results

On March 16, 2020, we circulated a simple survey on COVID-19 incidence and diagnostic and preventative measures. A web-based form was sent by email to 89 addressees, who work in pediatric hematology/oncology (PH/O) departments in many countries. Data was collected one day later. In total, 32 centers or countries provided data on COVID-19 incidence in children treated with chemotherapy or intensive immunosuppression in their institutions or countrywide (Table 1). The results are shown together with the COVID-19 incidences in general population.

Briefly, of more than 200 patients who were tested for SARS-CoV-2 in these PH/O departments, which care for close to 10,000 at-risk patients, only eight cases of proven infection were identified. Given that there is no general recommendation regarding testing of asymptomatic individuals, many centers only tested symptomatic patients, so the true rate of infection is not known. None of the reported cases required intensive care because of COVID-19. Case 1 was a febrile adolescent after mediastinal radiotherapy for osteosarcoma, no information was available regarding prior chemotherapy. Case 2 was a 16year girl with febrile neutropenia after adjuvant chemotherapy for hepatoblastoma. She received azithromycin and granulocyte colony stimulating factor (G-CSF), no pulmonary involvement was present and after 5 days she was free of both neutropenia and fever. Also case 3 had febrile neutropenia, after chemotherapy for a cervical rhabdoid tumor. There were no radiologic signs of pulmonary involvement but she required oxygen for nightly desaturations. She received G-CSF and azithromycin and after 10 days she was dismissed from hospital. Case 4 was a 6-year boy admitted in a hospital for a cisplatin cycle for hepatoblastoma, with a COVID-19-positive swab after the end of therapy; he was discharged without therapy and remained in a good condition. Cases 1-4 were also mentioned elsewhere (Balduzzi et al, submitted). Case 5 was a child with metastatic Ewing sarcoma who developed febrile neutropenia after their 5th cycle of chemotherapy. Case 6 was a child with Wilms' tumor who presented with fever and diarrhea after 6 weeks of chemotherapy; this child did have lymphopenia but not neutropenia. None of these two patients had respiratory symptoms, and both became afebrile within 12-24 hours. Both received hydroxychloroquine, and Case 5 also received Lopinavir-Ritonavir (LPV/r). Two more cases were reported two days after the survey responses were collected. One of them (case 7) was in febrile neutropenia treated for ALL and no data on outcome is available yet. The other one (case 9) was on maintenance treatment for ALL without typical symptoms, tested because his parents were COVID-19-positive; the anti-leukemic maintenance treatment was interrupted until two negative results will be obtained.

Discussion

To our knowledge, this is the first survey of pediatric oncology centers in SARS-CoV-2 affected areas. We found that the number of infected patients appears to be low, and that the few who were identified had mild and possibly self-limited infection.

The low rate of identified infection is somewhat surprising, as it is reasonable to assume that the pediatric patients with cancer would be at least as susceptible to infection with SARS-CoV-2 infection as their healthy peers. The SARS-CoV-2 does infect children in general, although lower severity of the infection makes children prone to be underreported[3,6]. Thus, at least in the countries with high COVID-19 incidence, either the transmission of SARS-CoV-2 was prevented by standard infection prevention measures, or cases remained undiagnosed as the course of the infection did not raise a suspicion of COVID-19. In some areas, the devastating overall situation made the diagnostics of mild cases a low priority.

The mild disease experienced by the three children in this study is in direct contrast to the only previously published case of which we are aware. An 8 year old child undergoing myelosuppressive chemotherapy for T-cell acute lymphoblastic leukemia in ALL in a Wuhan hospital developed respiratory failure over the course of 3 weeks, eventually requiring mechanical ventilation; the patient had not recovered at the time of the report[8] (and included in [3,9]). During the course of that patient's disease, CRP and IL-6 were only mildly elevated but ferritin levels were high (6417-15,758 ug/L). This is reminiscent of features of hemophagocytic lymphohistiocytosis, which has been previously described to co-occur with infections[12]. Possible correlation between the severity of infection and the composition and intensity of chemotherapy should be studied in larger cohorts.

The participating countries are gradually strengthening general preventative measures, usually aiming at social distancing, quarantines for the infected and contacts, clean hands and surfaces and cautious checking for possible symptoms – similarly to measures successfully applied in Hong Kong during the SARS epidemic in 2003[13].

In PH/O departments, precautions are always taken to protect patients from any infections. The degree of these precautions typically depends on the severity of immunosuppression and differs among hospitals[14]. Although our study portrays symptomatic COVID-19 as a rare finding among heavily immunocompromised children, at least in the first weeks of pandemics, other viruses do occasionally infect these patients in hospital wards despite these precautions[15]. The responders to this survey recommend taking additional measures during the COVID-19 epidemic to protect patients and staff from being either infected or in quarantine. As the epidemiological situation develops, only scientifically supported measures should remain in place, not to cause unwanted delays in the treatment of the underlying malignancies.

The overall experience with daily life in hospitals during the peak COVID-19 epidemics has been thoroughly described by Italian physicians (Balduzzi et al, submitted).

There are large differences among countries regarding the specific measures recommended. Most commonly, social contact is being minimized in the general population during high epidemic risk. Whole hospitals or hospital areas in Italy and Spain are designated as “dirty” (suspected or proven SARS-CoV-2 infection) and “clean” (no suspicious symptoms or SARS-CoV-2 test is negative) areas. Facial masks are recommended for all care givers and, if possible, for patients any time during personal contacts. Health professionals taking care of immunocompromised patients are separated into teams without mutual physical contact, to avoid simultaneous infection or preventative quarantine in the entire staff. This can be done by working on alternate days (unless the workload forbids it) or weeks and not sharing offices and common areas. Fewer or no in-person conferences take place. Children with respiratory symptoms are screened for SARS-CoV-2 before entering PH/O units. Outpatient visits for long-term surveillance patients are postponed. Immunosuppressed children are recommended to be isolated from general pediatric patients, where possible. Although these infection prevention measures might reduce the risk of SARS-CoV-2 transmission, they can also directly or indirectly complicate patient care. It can cause a shortage of clinical doctors, nurses, diagnosticians, and technical supportive staff, drug shortages, higher stress in accompanying parents, logistic problems with transfusion and transplant products, and organizational inaccuracies in clinical decision making process due to lack of meetings.

In conclusion, heavily immunocompromised patients in the PH/O wards remain at high potential risk of acquiring infectious diseases, including COVID-19. In a striking contrast, the current number of reported cases of COVID-19 among these patients is limited to a single previously reported case from China plus the four cases reported here. More research is needed to better understand the epidemiology of SARS-CoV-2 infection and COVID-19 in pediatric patients with cancer or other immunocompromised children. More cases are expected as the pandemic is only just unfolding in many countries. This flash survey, although providing a very early picture of COVID-19, shows that the disease may have a mild course even in children receiving anticancer chemotherapy. The risk of severe disease with COVID-19 in profoundly immunocompromised children is still unknown, and predictors of asymptomatic infection, mild disease or severe and life-threatening infection would help support the development of approaches to prevent as well as to optimize treatment of COVID-19 in this vulnerable patient population.

References

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA;2019.

2. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Epub ahead of print].

3. Lu X, Zhang L, Du H, et al. SARS-CoV-2 Infection in Children. N Engl J Med 2020;NEJMc2005073.

4. Wei M, Yuan J, Liu Y, Fu T, Yu X, Zhang Z-J. Novel Coronavirus Infection in Hospitalized Infants Under 1 Year of Age in China. JAMA 2020;129(6):802–804.

5. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. Clin Infect Dis [Epub ahead of print].

6. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med 2020;NEJMc2003717.

7. Dong Y, Mo X, Hu Y, et al. Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. Pediatrics [Epub ahead of print].

8. Chen Z, Xiong H, Li JX, et al. [COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report]. Zhonghua Xue Ye Xue Za Zhi 2020;41E004.

9. Sun D, Li H, Lu X-X, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World J Pediatr [Epub ahead of print].

10. Korean Society of Infectious Diseases, Korean Society of Pediatric Infectious Diseases, Korean Society of Epidemiology, Korean Society for Antimicrobial Therapy, Korean Society for Healthcare-associated Infection Control and Prevention, Korea Centers for Disease Control and Prevention. Report on the Epidemiological Features of Coronavirus Disease 2019 (COVID-19) Outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci 2020;35(10):e112.

11. Ogimi C, Englund JA, Bradford MC, Qin X, Boeckh M, Waghmare A. Characteristics and outcomes of coronavirus infection in children: The role of viral factors and an immunocompromised state. J Pediatric Infect Dis Soc 2019;8(1):21–28.

12. Janka GE, Lehmberg K. Hemophagocytic syndromes - An update. Blood Rev 2014;28(4):135–142.

13. Li CK, Zee B, Lee J, Chik KW, Ha SY, Lee V. Impact of SARS on development of childhood acute lymphoblastic leukaemia. Leukemia 2007;21(7):1353–1356.

14. Klein K, Hasle H, Abrahamsson J, De Moerloose B, Kaspers GJL. Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin–Frankfürt–Münster (I-BFM) study group. Br J Haematol 2018;183(1):87–95.

15. Shachor-Meyouhas Y, Zaidman I, Kra-Oz Z, Arad-Cohen N, Kassis I. Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department. J Pediatr Hematol Oncol 2013;35(2):124–128.

Table 1 – Flash survey results

Investigator	Name of institution	Countrywide incidence of COVID-19 per million	Number of pts. on chemotherapy	tested for COVID-19	proven COVID-19 Total
C.R., B.B., A.Bal.	PH/O Unit, University of Milano-Bicocca, MBBM Foundation, ASST Monza, Italy	463	100	2	0
	PH/O, Università degli Studi di Padova, Italy		150	88	0
	Italy (entire country)		1500 - 2000	not known	4 (cases 1-4)
J-P.B.	Kinderspital Zürich, Switzerland	317	100	1 - 10	0[a]
S.R.	Hospital Sant Joan de Déu de Barcelona, Spain	244	250	0	0
N.D.P.	Hospital Virgen de la Salud, Spain		35	3	1 (case 5)
M. dP.C., M.E.V.A.	Hospital General Universitario de Albacete, Spain		4	1	1 (case 6)
K.S.	Copenhagen University Hospital, Rigshospitalet, Denmark	160	90 - 100	1 - 10	0
	Denmark (entire country)		180	1 - 10	0
A.A.	St Anna Kinderspital, Vienna, Austria	148	100	1 - 9	0
	Austria (entire country)		250	not known	0
P.G.	PH/O, Karolinska University Hospital, Stockholm, Sweden	116	100	0[a]	0[a]
K.M.	Sahlgrenska University Hospital, Gothenburg, Sweden		100	5	0
J.T.B.vd W.	UZ Brussel, Belgium	107	10	0	0
A.Bar.	PH/O, University Hospital Robert Debré, Paris, France	102	150	5	0
R.P.	Princess Maxima Center, Netherlands	99.5	900	5 – 10[b]	0
M.Sch.	Childrens Hospital Medical Center Schleswig-Holstein, Kiel, Germany	95.2	50	5	0
T.B., A.Bo.	PH/O and Clinical Immunology, Heinrich Heine University Düsseldorf, Germany		125	50	0
G.E.	PH/O, Universtitätsklinikum Eppendorf, Germany		100	5	0
M.L.	University Hospital Schleswig-Holstein, Campus Lübeck, Germany		24	2	0
M.St.	Medizinische Hochschule Hannover, Germany		100	5	0[a]
O.S.	National Children's Cancer Service, Children's Health Ireland at Crumlin, Dublin, Ireland	59.1	not known	not known	0
A.E.J.Y.	Singapore (entire country)	45.5	200	10	0

S.E.	Schneider Children's Medical Center of Israel	37.4	220	3	0
O.H.	Czechia (entire country)	37	250	2 - 10	0
A.V.	Great Ormond Street Hospital, UK	22.7	500	5	0
C.-K.L.	Hong Kong Children's Hospital	22.4	210	3	0
H.A.	University of Malaya, Kuala Lumpur, Malaysia	20.8	100	1	0
	Malaysia (entire country)		500	1 - 10	0
A.K.	Slovakia (entire country)	17.8	180	3	0
L.D.	The Children's Hospital at Westmead, Australia	17.7	300	0	0
	Australia (entire country)		1740	not known[c]	0
R.F.	LAU MC-Rizk Hospital,Beirut, Lebanon	17.6	20	1	0
J.L.	University Children's Hospital, Belgrade, Serbia	8.2	30	0	0
A.M.	Hokkaido University in Sapporo, Japan	6.9	30	0	0
	Japan (entire country)		2500 - 4000	not known	0
J.Sty.	Poland (entire country)	5.8	1048	13	0
G.O.	PH/O, University of Pécs, Hungary	5.2	7	0	0
G.K.	Hungary (entire country)		250	4	0
M.F.	Hospital de Pediatría, "Prof. Garrahan", Argentina	1.5	90 - 100	1 - 10	0

Data reflect a situation as of March 17, 2020. [a]Two positive cases were diagnosed on March 21, 2020 - in Switzerland (case 7) in Stockholm, Sweden (case 8) and in Hannover, Germany (case 9), all are also mentioned in Results. [b]Additional 80 cases screened by March 19, 2020, all were negative. [c] As of March 26, 47 to 60 cases were tested in 7 Australian hospitals within ANZCHOG group, all were negative. PH/O = (Department of) Pediatric Hematology/Oncology.